Document is current
Any future updates will be listed below
-
Authors
Mima, Shunsuke https://orcid.org/0009-0008-6980-453X
Abe, Yoshiro
Yamasaki, Hiroyuki
Bando, Mayu
Nagasaka, Shinji
Yamashita, Yutaro
Mineda, Kazuhide
Yoshida, Sumiko
Endo, Itsuro
Matsuhisa, Munehide
Takaiwa, Masahiro
Hashimoto, Ichiro
-
Funding
Funding for this research was provided by:
Abbott Japan
Sanofi K.K.
Dainippon Sumitomo Pharma
Novo Nordisk Pharma
Terumo
Eli Lilly Japan
Kyowa Hakko Kirin
Boehringer Ingelheim Japan
Origuru Therapeutics
Japan Association for Diabetes Education and Care
- License Information
-
More Information
Article History
Received: 1 September 2024
Accepted: 26 December 2024
First Online: 14 January 2025
Declarations
:
: Munehide Matsuhisa has received lecture fees from Abbott Japan, Sanofi, Sumitomo Pharma, Novo Nordisk Pharm, Terumo, Eli Lilly JP, Kyowa Kirin, Boehringer Ingelheim, and Origuru Therapeutics. In addition, he has received research funding from the Japan Association for Diabetes Education and Care.Ethical aprrovalAll procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (the Ethics Committee of Tokushima University Hospital / 2021/6/28 / 4012) and with the Helsinki Declaration of 1964 and later versions. Informed consent or a substitute for it was obtained from all participants for being included in the study.
